Biogen Inc. – Common is a current holding in our US high conviction portfolio.
The stock price rallied following the FDA decision, which was announced earlier this week, to approve Biogen’s drug Aducanumab, a treatment for Alzheimer’s disease.


Biogen Inc. – Common is a current holding in our US high conviction portfolio.
The stock price rallied following the FDA decision, which was announced earlier this week, to approve Biogen’s drug Aducanumab, a treatment for Alzheimer’s disease.

Join Investor Signals today and start your journey to better, more disciplined returns.